#Canada #Toronto #ctDNA #Oncology Trials #Xtalks

Webinar on Recent Changes in Oncology Trial Design

The landscape of oncology trial design is continuously evolving, and a crucial upcoming webinar hosted by Xtalks will shed light on the latest developments. Participants will explore the significant shifts that have occurred over the past 18 months, following essential guidelines such as the Prostate Cancer Working Group 4 recommendations and the updated Eastern Cooperative Oncology Group performance status.

This insightful session will cover the transition of circulating tumor DNA (ctDNA), minimal residual disease (MRD), and advanced imaging biomarkers from supplementary measures to primary endpoints across various tumor types. The expert speakers will discuss what regulatory bodies expect regarding patient-reported outcomes and the initiatives like Project Patient Voice that are shaping these expectations.

Understanding the Current Landscape

The last year and a half have marked a pivotal change in oncology trial designs. The Prostate Cancer Working Group has redefined trial structures for advanced prostate cancer, incorporating innovative techniques such as PSMA PET imaging and ctDNA dynamics. This progress highlights a move towards more personalized and scientifically robust methodologies.

Moreover, the traditional performance scales used to determine trial eligibility are now being scrutinized, especially regarding their applicability to older and frailer patients. The integration of patient-reported outcomes into regulatory frameworks is more crucial than ever, signifying a shift towards considering patients' perspectives in clinical research.

The Key Focus Areas of the Webinar

The upcoming webinar will encompass three primary areas critical to modern oncology trials:
1. Evolving Clinical Trial Design: A discussion on how new endpoints such as ctDNA, MRD, and advanced imaging biomarkers improve decision-making in trials. The speakers will address how these advancements can bolster scientific inquiry while minimizing the risk of complications in trial structures.
2. Eligibility Landscape: Insights into how factors like performance status, age, and biomarker stratification are under review for their impact on patient recruitment, particularly in early-phase trials. This segment emphasizes the need to balance inclusivity with scientific rigor.
3. Designing Effective Protocols: The final part will explore what constitutes a strong protocol that leverages recent scientific and methodological advancements. Participants will learn to craft trial designs that comply with evolving FDA regulations and maximize practical implementation.

Who Should Attend

This webinar is tailor-made for decision-makers within biotech and pharmaceutical sectors who are involved in writing oncology protocols today. The timing, shortly after the ASCO 2026 conference, allows professionals to gather contemporary insights and action points to refine their ongoing research efforts.

Dr. Victor Moreno, Dr. Emiliano Calvo, and Estelle Guiheneuf are among the expert speakers who will steer this engaging session.

Sign Up Today!

Don't miss out on the opportunity to learn about the changing dynamics in oncology trials. Register for the webinar on June 24, 2026, at 11 AM EDT (5 PM CEST/EU-Central) and ensure your practices align with the latest scientific recommendations.

For further details or to secure your spot, visit the Xtalks website.

About Xtalks

Xtalks serves as the go-to resource for life science professionals, providing a platform for collaboration, knowledge sharing, and industry insights. Through webinars, articles, and expert interviews, it supports individuals in making informed decisions within an ever-evolving environment.

Join us and be part of the transformation in oncology trial design, making strides towards a more effective future in cancer research.